Roof Eidam Maycock Peralta LLC Has $817,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Roof Eidam Maycock Peralta LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,247 shares of the biopharmaceutical company’s stock after selling 1,748 shares during the quarter. Roof Eidam Maycock Peralta LLC’s holdings in Pfizer were worth $817,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in PFE. Olistico Wealth LLC bought a new stake in shares of Pfizer in the 2nd quarter worth $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer during the second quarter worth $29,000. Quarry LP purchased a new position in Pfizer in the second quarter worth $31,000. Trivant Custom Portfolio Group LLC boosted its holdings in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. bought a new position in Pfizer during the second quarter valued at about $34,000. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

PFE stock opened at $28.93 on Tuesday. The firm has a 50 day simple moving average of $29.07 and a two-hundred day simple moving average of $28.47. The stock has a market cap of $163.93 billion, a PE ratio of -482.17, a P/E/G ratio of 1.02 and a beta of 0.67. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period in the previous year, the business earned $0.67 earnings per share. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, analysts predict that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.81%. Pfizer’s dividend payout ratio is -2,800.00%.

Analysts Set New Price Targets

PFE has been the topic of a number of research reports. UBS Group boosted their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Barclays lifted their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Wells Fargo & Company increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.91.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.